Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.
about
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancerAmifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancerTreating malignant glioma in Chinese patients: update on temozolomidePhase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected SubjectsSodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluationStereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trialApproach for Classification and Severity Grading of Long-term and Late-Onset Health Events among Childhood Cancer Survivors in the St. Jude Lifetime Cohort.Impact of treatment planning and delivery factors on gastrointestinal toxicity: an analysis of data from the RADAR prostate radiotherapy trial.Single brain metastasis: radiosurgery alone compared with radiosurgery plus up-front whole-brain radiotherapy.Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysisHigh activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneHematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin.Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases.A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility studyConcurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single instituteWeekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinomaFeasibility, safety, and outcome of frameless image-guided robotic radiosurgery for brain metastases.Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients.Impact on Loco-regional Control of Radiochemotherapeutic Sequence and Time to Initiation of Adjuvant Treatment in Stage II/III Rectal Cancer Patients Treated with Postoperative Concurrent RadiochemotherapyManagement of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both.Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer.Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients.Radiation-Induced Oral MucositisPrognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysisA comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: analysis of 62 patients.Endoscopic scoring of late gastrointestinal mucosal damage after adjuvant radiochemotherapyRadiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapseSingle brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection.Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer.The different dose-volume effects of normal tissue complication probability using LASSO for acute small-bowel toxicity during radiotherapy in gynecological patients with or without prior abdominal surgery.
P2860
Q24240279-1092FB51-A681-4794-8D3E-2F3F151A8736Q24240711-17698F8A-9C01-4313-8685-32B580242372Q26863755-7CBDC8D6-DC25-492F-B4B7-D04F93EF1C0BQ27486108-99A5CD7B-0695-4FD2-9783-45CCFBA76574Q28304984-CF8C7E59-1DC5-4BC3-94AB-684E1586E7EDQ28709611-E96536C1-E226-4654-9892-2A4DB0C48F16Q30239868-03A4FF2B-4D44-4295-AB9A-773F29350EA2Q30877686-8AB143CC-7F07-4142-83FB-90C1AF68EBC1Q31039691-75AE64BA-B9A1-412D-B914-FF11A35F440FQ33242477-588929C2-312B-4361-9B57-BDA92330B1B1Q33265638-A78347B5-921A-4D0B-BE60-1201B214D780Q33343008-DA407C24-52AA-42C6-8E33-E1EA764D7E07Q33364465-3A9CD55B-27DC-4A1C-87EC-5FF566783009Q33369694-682C5E24-E513-49C1-ABAE-A78869646551Q33378971-8A01561E-AF23-41B1-95F3-F16B3F6C0B8EQ33379651-F68ADDFC-04E1-4738-BF2D-20C8AEA9C914Q33379811-2CB28CA1-B727-4102-8CC8-4E7BAA9D3650Q33387995-1830553F-EA0B-4C8E-83B8-B543F52747C5Q33391818-61F004A5-DA8A-463D-B1D9-745C4A233FFDQ33395704-FBB0C880-FEA5-40A6-B3D3-E749F5DDC537Q33395721-FA39F9D0-5331-4B4B-A7FD-0FC993554977Q33402602-77D38869-8560-41FA-8B6F-76E21784EF0BQ33407844-5E0E30C9-E8C9-4AF6-9A4D-6E88DBFEA725Q33409519-2CE8F7D6-37A7-440F-84A8-31C23B9F1691Q33418020-12BE0E68-6F3E-45D9-9295-286806C2B1D3Q33435812-59D5D53E-0318-4E8F-913E-1C8C3AC7D062Q33508604-D32AAE62-AF2E-42FB-A2F2-109A6BF03100Q33532191-03DD6CF8-BCE5-446C-8131-965EEFAA93BFQ33619231-47286336-8435-4730-A5E6-C5F2336DE8EFQ33673488-D89DD9AD-B620-4540-BD48-48743EDD106BQ33682891-B8D88BED-AAD5-4F3F-96D1-76889D3485E9Q33692477-8E685E90-EC74-4B99-BA95-4C21A79D274AQ33711362-707B2D88-C7F0-420C-A4E8-D2572D80AD2DQ33729104-C3670335-3A28-4CE0-A999-A07045A063C7Q33755887-1BA5C423-12D9-4351-B978-C90CBC3B2CAEQ33867589-B88E8E9C-063A-4844-ACF5-E84ECD440FFBQ33960861-3E6D3577-05A8-41C7-9904-B39B16799C7BQ33962077-823DA1C7-8F00-46BF-84E1-4157919308B3Q33993645-601461EF-0C7D-4FBC-8814-D5789F14AD26Q34014421-F5408E1C-9BBA-4494-98CB-E3EC1ECAB8DA
P2860
Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Common toxicity criteria: vers ...... tment: impact on radiotherapy.
@ast
Common toxicity criteria: vers ...... tment: impact on radiotherapy.
@en
type
label
Common toxicity criteria: vers ...... tment: impact on radiotherapy.
@ast
Common toxicity criteria: vers ...... tment: impact on radiotherapy.
@en
prefLabel
Common toxicity criteria: vers ...... tment: impact on radiotherapy.
@ast
Common toxicity criteria: vers ...... tment: impact on radiotherapy.
@en
P2093
P1476
Common toxicity criteria: vers ...... tment: impact on radiotherapy.
@en
P2093
Gunderson L
McCormick B
Morrisintegral M
P356
10.1016/S0360-3016(99)00559-3
P407
P577
2000-04-01T00:00:00Z